ERBB2 and neoplasm: Trastuzumab can block HER2 signaling and activate the antitumor immune response depending on the activation of antibody-binding Fc receptors (FcRs) to destroy tumor cells (Gennari et al., 2004; Spector and Blackwell, 2009; Stagg et al., 2011).